Clinuvel Pharmaceuticals LimitedASX: CUV

Canadian New Drug Submission for SCENESSE in EPP filed

· Issued by Clinuvel Pharmaceuticals Limited

Filed with ASX · · 3 pages · English

Summary by 6ix AI

Clinuvel Pharmaceuticals Limited has filed a New Drug Submission to Health Canada for SCENESSE® to treat erythropoietic protoporphyria (EPP), aiming to be the first approved treatment for this condition in Canada. The submission includes data that supported previous approvals from other regulatory bodies and highlights the ongoing Patient Special Access Program for Canadian patients. The company has trained multiple specialty centers in Canada to facilitate treatment access pending regulatory approval.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Clinuvel Pharmaceuticals Limited on 6ix

Story so far

Earlier from Clinuvel Pharmaceuticals

Later from Clinuvel Pharmaceuticals

All Clinuvel Pharmaceuticals news releases